Drug Type TCR fusion protein |
Synonyms autologous GPC3-solid tumor program (TCR2 Therapeutics), TRuC-T cells targeting GPC3 (TCR2 Therapeutics) |
Target |
Mechanism GPC3 modulators(Glypican-3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | 08 Mar 2023 |